Article citationsMore>>

Lorenc, R.S. and Resch, H., on Behalf of the Members of the “2nd Summit on Osteoporosis—Central and Eastern Europe (CEE)” (2009) Management of Osteoporosis in Central and Eastern Europe (CEE): Conclusions of the “2nd Summit on Osteoporosis—CEE”, 21-22 November 2008, Warsaw, Poland. Archives of Osteoporosis, 4, 1-8.
http://dx.doi.org/10.1007/s11657-009-0028-6

has been cited by the following article:

• TITLE: Comparison of Strontium Ranelate and Alendronate Sodium Treatment among Post-Menopausal Women

  AUTHORS: Unal Eren, Tuba Eren

  KEYWORDS: Osteoporosis, Menopause, Strontium Ranelate, Alendronate Sodium

  JOURNAL NAME: Open Journal of Obstetrics and Gynecology, Vol.6 No.2, February 16, 2016

  ABSTRACT: Growing rates of osteoporosis in the whole world is a serious health problem. As the “expected lifetime” is prolonged, population of elderly women with chronic diseases who require long-term treatment increases. This study aimed to compare antiresorptive treatment—that has become a classic treatment in the light of Canadian Guideline for osteoporosis—with the antiresorptive plus osteoblastic activity inducing treatment modality. The clinical and laboratory results of patients treated with a single dose of 2 mg Strontium ranelate sachet (Protelos ®) or alendronate sodium used weekly 70 mg tablet (Fosamax ®once a week tablet) for 12-months were compared. Treatment compliance has been questioned. A hundred women in post-menopausal period were included in this study. Patient satisfaction survey among the group of strontium ranelate was unsatisfactory. Among patients using alendronate sodium the ease of use in this sense obtained a rate of 91% satisfaction from patients.